- Phase III POLARIX trial showed Polivy plus R-CHP was the first treatment in two decades to significantly improve outcomes in newly diagnosed diffuse large B-cell lymphoma (DLBCL) versus the standard of care1
- Pivotal data on mosunetuzumab, a potential first-in-class CD20xCD3 T-cell engaging bispecific antibody, showed high response rates in relapsed or refractory follicular lymphoma (FL)2
- HAVEN 6 phase III interim data demonstrated Hemlibra’s favourable safety and efficacy profile in people with moderate or mild haemophilia A3
Roche moment blazoned that new data from its expansive haematology portfolio will be presented at the American Society of Hematology (ASH) Annual Meeting and Exposition from 11-14 December 2021. Roche motes will be featured in further than 90 objectifications, including 17 oral donations, showcasing new immunotherapies, unique treatment combinations, the operation of new endpoints, and fixed- duration rules.
Results from three vital studies will be featured
First Donation of efficacity and safety data from the phase III POLARIX study as a late- breaking abstract and in the ASH press programme. POLARIX met its primary endpoint of perfecting progression-free survival, showing Polivy ® (polatuzumab vedotin) plus MabThera ®/ Rituxan ® (rituximab), cyclophosphamide, doxorubicin, and prednisone (R-CHP) reduced the liability of complaint worsening or death, versus the standard-of- care, MabThera/ Rituxan plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP), for people with recently diagnosed verbose large B- cell carcinoma (DLBCL). The safety profile was similar for Polivy plus R-CHP versus R-CHOP.1 POLARIX is being conducted in collaboration with The Lymphoma Study Association (LYSA) and The Lymphoma Academic Research Organisation (LYSARC).
Vital results from the phase I/ II GO29781 study, presented for the first time and featured in the ASH press programme, showing mosunetuzumab, a CD20xCD3 T- cell engaging bispecific antibody immunotherapy, achieved high response rates with a manageable safety profile. These data suggest that it could be a new treatment option for people with regressed or refractory follicular carcinoma (FL) who have entered two or further previous curatives.2 FL is the most common idle ( slow growing) form ofnon-Hodgkin carcinoma, a type of blood cancer, which frequently returns after original remedy.4
Interim data from the phase III HAVEN 6 study, which demonstrated the favourable safety and efficacity profile of Hemlibra ® (emicizumab) in people with moderate or mild haemophilia A without factor VIII impediments.3 This case population has historically not used precautionary ( precautionary) treatments, probably due to delayed or missed opinion and a lack of treatments and treatment guidelines, meaning these cases have a significant unmet clinical need.5, 6
.“ For 20 times, we’ve remained married to heightening our understanding of numerous benign and nasty blood diseases in order to more meet the critical requirements of cases with these conditions,” said Levi Garraway,M.D.,Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development. “ Our data at ASH support our conviction that following the wisdom and developing protean treatment approaches leads to bettered issues for cases in decreasingly meaningful ways.”
Data presented at ASH by Roche span multitudinous blood conditions, including carcinoma, leukaemia, multiple myeloma and haemophilia. Fresh data to be presented include streamlined results for three T- cell engaging bispecific antibody immunotherapies glofitamab and mosunetuzumab, targeting CD20 and CD3; and cevostamab, targeting FcRH5 and CD3.
Roche will be hosting a Live Media Event named‘ Reconsidering treatment norms to ameliorate issues for cases with blood diseases’on Wednesday 15 December, offering an exclusive occasion to hear from experts about the vital data being presented. Register then to pierce the Roche Haematology Newsroom, available from Friday 26 November, where you ’ll be suitable to attend the Live Media Event and find accoutrements to further explain and give environment to Roche’s nasty andnon-malignant data.
About Roche in haematology
Roche has been developing drugs for people with nasty andnon-malignant blood conditions for over 20 times; our experience and knowledge in this remedial area runs deep. Moment, we’re investing further than ever in our trouble to bring innovative treatment options to cases across a wide range of haematologic conditions. Our approved drugs include MabThera ®/ Rituxan ® (rituximab), Gazyva ®/ Gazyvaro ® (obinutuzumab), Polivy ® (polatuzumab vedotin), Venclexta ®/ Venclyxto ® (venetoclax) in collaboration with AbbVie, and Hemlibra ® (emicizumab). Our channel of investigational haematology drugs includes T- cell engaging bispecific antibodies, glofitamab and mosunetuzumab, targeting both CD20 and CD3, and cevostamab, targeting both FcRH5 and CD3; Tecentriq ® (atezolizumab), a monoclonal antibody designed to bind with PD-L1; and crovalimab, ananti-C5 antibody finagled to optimise complement inhibition. Our scientific moxie, combined with the breadth of our portfolio and channel, also provides a unique occasion to develop combination rules that aim to ameliorate the lives of cases indeed further.
Roche is a global colonist in medicinals and diagnostics concentrated on advancing wisdom to ameliorate people’s lives. The combined strengths of medicinals and diagnostics, as well as growing capabilities in the area of data- driven medical perceptivity help Roche deliver truly personalised healthcare. Roche is working with mates across the healthcare sector to give the stylish care for each person.
Roche is the world’s largest biotech company, with truly discerned drugs in oncology, immunology, contagious conditions, ophthalmology and conditions of the central nervous system. Roche is also the world leader in in vitro diagnostics and towel- grounded cancer diagnostics, and a frontrunner in diabetes operation. In recent times, the company has invested in genomic profiling and real- world data hookups and has come an assiduity- leading mate for medical perceptivity.
Souorce link: https://www.roche.com/